Kariya Pharmaceuticals ApS

CVR 39270684 · Private limited company (ApS) · Active · Medium risk

Kariya Pharmaceuticals ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 2.0% over the next 12 months, which is 1.4 times the average for Danish companies. 8 annual reports have been published, of which 4 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -25.2m and a net result of DKK -26.5m. CEO: Christian Hölscher.

Bankruptcy risk for Kariya Pharmaceuticals ApS

2.0%
probability of bankruptcy within 12 months
Medium risk

1.4 × the average (1.41%) · higher risk than 82% of active Danish companies

Lowest riskHighest risk

Increases the risk

Equity ratio< -50% · bankruptcy rate 19.3%2.2×
Share of late annual reports50%–75% · bankruptcy rate 18.4%2.1×
Negative equityYes · bankruptcy rate 17.5%2.0×
Equity vs. share capital< 0× · bankruptcy rate 17.3%2.0×
Return on assets< -20% · bankruptcy rate 16.7%1.9×
Going-concern uncertaintyYes · bankruptcy rate 16.3%1.9×
Number of auditors (historical)0 · bankruptcy rate 12.5%1.4×
Website registeredYes · bankruptcy rate 12.0%1.4×

Reduces the risk

Reinstated after compulsory dissolutionYes · bankruptcy rate 0.0%0.00×
Time at current address5+ yrs · bankruptcy rate 3.1%0.35×
Time since new CEO5+ yrs · bankruptcy rate 3.8%0.43×
Auditor's statementCompilation · bankruptcy rate 5.6%0.64×
Registered owners4+ · bankruptcy rate 5.7%0.65×
Reporting classReporting class B · bankruptcy rate 5.7%0.65×
Has a boardYes · bankruptcy rate 6.0%0.68×
Capital changes3+ · bankruptcy rate 6.2%0.70×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
39270684
Status
Active
Company type
Private limited company (ApS)
Founded
(8 years)
Address
Ole Maaløes Vej 3
2200 København N
Municipality
København
Industry
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Share capital
DKK 55k
Auditor
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab
Audit opted out
Yes

Warning signs

Annual reports filed late4 of 8
Missing annual reportNo
Negative equityYes
Equity ratio-64.7%
Current ratio61%
Moves (last 2 years)0
CEO changes in total3
CEO's previous bankruptcies0
Other companies at the address167
Going-concern uncertaintyYes

Financials and key figures

Financial year202520242023
Gross profitDKK -32.1mDKK -3.6mDKK -10.2m
Net profitDKK -26.5mDKK -2.6mDKK -8.0m
EquityDKK -25.2mDKK 1.3mDKK -6.4m
Total assetsDKK 38.9mDKK 2.3mDKK 2.0m
CashDKK 4,127DKK 2.1m–
Short-term debtDKK 64.2mDKK 1.0m–
Avg. employees01–

Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025187 Late
1 Jan 2024 – 31 Dec 2024202 Late
1 Jan 2023 – 31 Dec 2023179
1 Jan 2022 – 31 Dec 2022186 Late
1 Jan 2021 – 31 Dec 2021191 Late
1 Jan 2020 – 31 Dec 2020179
1 Jan 2019 – 31 Dec 201934
18 Jan 2018 – 31 Dec 2018142

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
CEOChristian HölscherCurrent
CEOIan Rodney Laquian
BoardClaus Elsborg OlesenCurrent
BoardIan Rodney LaquianCurrent
BoardMikael Søndergaard ThomsenCurrent
BoardChristian HölscherCurrent
BoardJohn ConnellCurrent
Owner (5%)Thomsen Pharma ApSCurrent
Owner (25%)JUMIKA Holdings ApSCurrent
Owner (20%)MAC Clinical Research Finance Ltd.Current
Owner (25%)Hoelscher Holdings LimitedCurrent
Owner (50%)Ian Rodney Laquian
Owner (33%)Christian Hölscher
Owner (33%)JUMIKA Holdings ApS
Owner (5%)Thomsen Pharma ApS
Owner (10%)MAC Clinical Research Finance Ltd.
Owner (33%)Hoelscher Holdings Limited
FounderJUMIKA Holdings ApSCurrent
FounderChristian HölscherCurrent

The CEOs' other companies

Ian Rodney Laquian – 5 other companies, of which 1 bankrupt

Address history (2 moves)

Ole Maaløes Vej 3, 2200 København N
c/o Ian Laquian, Ole Maaløes Vej 3, 2200 København N
c/o Ian Laquian, Johannevej 7, 2920 Charlottenlund

Former names

Kariya Pharmaceuticals ApS – now
Kariya Pharmaceuticals IVS –

Other companies at the same address

Similar companies in København

Questions and answers about Kariya Pharmaceuticals ApS

Has Kariya Pharmaceuticals ApS gone bankrupt?

No, Kariya Pharmaceuticals ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Kariya Pharmaceuticals ApS?

Our model estimates a bankruptcy risk of 2.0% over the next 12 months (medium risk), which is 1.4 times the average for Danish companies.

Who is the CEO of Kariya Pharmaceuticals ApS?

Christian Hölscher is the CEO of Kariya Pharmaceuticals ApS.

Who is the auditor of Kariya Pharmaceuticals ApS?

Kariya Pharmaceuticals ApS most recently used PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab.

When was Kariya Pharmaceuticals ApS founded?

Kariya Pharmaceuticals ApS was founded on 18 January 2018.

What is the equity of Kariya Pharmaceuticals ApS?

Equity was DKK -25.2m according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.